China Grants World-First Market Approval to Implantable BCI for Spinal Cord Injury

Commercial licensing of an invasive neural implant echoes the 1984 FDA approval of the first cochlear implant and the 1997 approval of deep-brain stimulators—milestones that shifted once-experimental neurosurgical gadgets into routine therapy. China’s move fits a decades-long trend: states using regulatory agility and industrial policy to leapfrog in frontier tech (as Japan did with semiconductors in the 1970s or South Korea with stem-cell therapies in the 2000s). By awarding the inaugural market authorization ahead of the U.S. FDA or Europe’s EMA, Beijing signals a willingness to accept higher early-stage risk to accelerate a strategic neurotech sector and rival firms like Neuralink. Whether this moment proves transformative or cautionary will depend on long-run safety data and public acceptance, but if successful it could mark the beginning of routine human-machine symbiosis— a step that, on a century timescale, would sit alongside antibiotics and microprocessors as technologies that rewired daily life.